Bladder Cancer - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Bladder Cancer Emerging Therapy and TPP Insights

Thelansis's "Bladder Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Bladder Cancer Overview

Bladder cancer is the most common malignancy of the urinary tract, with urothelial carcinoma representing the predominant histological subtype, arising from the transitional epithelium lining the bladder mucosa. Tobacco smoking, occupational aromatic amine exposure, chronic bladder inflammation, and cyclophosphamide exposure are established risk factors, with somatic mutations in FGFR3, TP53, RB1, and PIK3CA driving oncogenic transformation across non-muscle-invasive and muscle-invasive disease spectrums. Patients present with painless macroscopic haematuria - the cardinal symptom - alongside urinary frequency, urgency, and dysuria; cystoscopy with biopsy remains the diagnostic gold standard, supplemented by upper tract imaging and CT urography. Non-muscle-invasive bladder cancer is managed endoscopically via transurethral resection, with intravesical BCG immunotherapy reducing recurrence and progression risk in high-risk disease; pembrolizumab is approved for BCG-unresponsive carcinoma in situ. Muscle-invasive disease warrants neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy or bladder-preserving trimodality therapy. Metastatic disease is addressed with platinum-based chemotherapy, while maintenance avelumab immunotherapy following platinum response has demonstrated meaningful survival benefit. Erdafitinib targets FGFR3-altered metastatic disease, and enfortumab vedotin - a Nectin-4 directed antibody-drug conjugate - alongside pembrolizumab represents a transformative first-line metastatic standard. Prognosis varies with stage; multidisciplinary management, surveillance cystoscopy, and patient-centred quality-of-life optimisation are integral to long-term care.

Key Highlights

• In Germany, survival-adjusted prevalent Bladder Cancer cases are projected to increase from 727,014 in 2025 to 777,528 by 2035.
• Rising aging population and smoking-related risk burden continue to drive disease prevalence.
• Increasing adoption of immunotherapies and targeted agents is reshaping the treatment landscape.
• Persistent unmet need exists in advanced and recurrent bladder cancer management.

Market Overview

• The Italy Bladder Cancer market is projected to grow from USD 420 million in 2025 to USD 990 million by 2035.
• Market growth is driven by increasing uptake of immuno-oncology therapies and improved diagnosis rates.
• Future expansion will depend on advances in targeted therapies and combination treatment strategies.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Merck Sharp & Dohme LLC
• Ferring Pharmaceuticals
• ImmunityBio, Inc.
• Lipac Oncology LLC
• Daiichi Sankyo
• UroGen Pharma Ltd.
• CG Oncology, Inc.
• Astellas Pharma Global Development, Inc.
• Zhuhai Beihai Biotech Co., Ltd.
• ALX Oncology Inc.
• Hoffmann-La Roche
• Protara Therapeutics
• Monopar Therapeutics
• Eli Lilly and Company
• Incyte Corporation
• ViroMissile, Inc.
• Genentech, Inc.
• Palleon Pharmaceuticals, Inc.
• NGM Biopharmaceuticals, Inc.
• Toray Industries, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• AstraZeneca
• Sensei Biotherapeutics, Inc.
• Beijing Biotech
• OncoC4, Inc.
• MacroGenics
• Pfizer
• OncoNano Medicine, Inc.
• Medicenna Therapeutics, Inc.
• EvolveImmune United, Inc.